On December 18, 2014, Revive Therapeutics Ltd. (“Revive”) closed a public offering of 4,996,500 units (“Units”) at a price of $0.60 per Unit for gross proceeds of $2,997,900. Each Unit was comprised of one common share and one warrant entitling the holder thereof to purchase one additional common share for $0.85 for a period of two years from the date of issuance, subject to acceleration under certain circumstances.

Revive’s public offering was led by Beacon Securities Limited (“Beacon”) as the sole agent and bookrunner. Beacon was paid a cash commission and 349,755 compensation options, each such option entitling the holder to purchase one Unit for $0.60 for a period of two years from the date of issuance.

Peterson Law acted for Revive with a team that included Dennis Peterson.